Thoracic surgery for ovarian cancer recurrence

  • V.V. Boyko State Establishment "Zaitsev V.T. Institute of General and Emergency Surgery of the Academy of Medical Sciences of Ukraine"
  • K.V. Kharchenko Kyiv City Clinical Oncology Centre
  • R.I. Vereshchako Bogomolets National Medical University
  • G.O. Vakulenko Bogomolets National Medical University
Keywords: ovarian cancer, recurrence, surgery, secondary cytoreduction, organs of the chest cavity

Abstract

Aim. Safety, efficiency and diagnostic value of diagnostic and curative thoracic surgical interventions were the objectives of current research dedicated to patients with recurrent ovarian cancer.

Materials and Methods. Retrospective analysis of medical records of patients with recurrent ovarian cancer, on whom surgical interventions were performed at the State Establishment "Zaitsev V.T. Institute of General and Emergency Surgery of the Academy of Medical Sciences of Ukraine" during January 2010 - December 2015. Recurrence localization was limited by the organs of the thoracic cavity. Both diagnostic and cytoreductive surgical interventions were taken into account.

Results and Discussion. Forty three patients met the search criteria. In 11 cases (26%) more than one thoracic localization was diagnosed. Thoracoscopy (n=36; 84%) allows to assess the state of parietal and visceral pleura, to perform the dissection of pleural conjunctions, to determine the extension of pleural involvement and to take a biopsy from its surface. Possibility and feasibility of partial pleverectomy was established thoracoscopically (n=7, 16%). Pleurodesis (n=16; 37%) was performed in order to stop malignant recurrent pleural effusion. Pleurodesis effectiveness: complete remission (n=11; 69%); partial remission (n=4; 25%); progression of the disease (n=1; 6%). Mediastinoscopy was performed in 18 patients (42%) with radiological signs of mediastinal lymphadenopathy. In 12 cases (28%) cancer etiology had been confirmed and further lymphadenectomy was performed. In other cases (n=6; 14%), lymphadenopathy was not malignant with no subsequent surgery. Surgeries for lung parenchyma were the following: atypical lung resection (n=17, 40%), segmentectomy (n=3, 7%), lobectomy (n=2, 5%). Postoperative complications and mortality were 9% (n=4) and 2% (n=1), respectively. Median overall survival for patients with the duration of recurrence-free period <12 months was 9 months, 12-24 months - 21 months, >24 months - 48 months (p<0.05). Isolated parenchymal or lymph nodes lesions were characterized by the most favorable prognosis. The median overall survival rate for lung parenchyma recurrence was 39 months, lymph nodes - 31 months, pleura - 13 months, with more than one localization - 8 months (p<0.05).

Conclusions. Recurrent ovarian cancer with  of thoracic organs, traditionally, is not considered from the perspective of surgical treatment. Diagnostic surgical interventions allow individualizing treatment. Secondary cytoreduction procedures are safe and do not affect the timing of adjuvant treatment. They are characterized by a positive effect on overall and recurrence-free survival, compared to chemotherapy treatment. The duration of the recurrence-free period affects the median survival after secondary cytoreduction. Isolated lung parenchyma lesion is characterized by the most favorable prognosis. Taking into account the high frequency of the chest cavity lesions in patients with ovarian cancer recurrence, not only the palliative care, but also the development of indications for cytoreductive surgery remains important, as a way to prolong survival.

References

Adachi M, Mizuno M, Mitsui H, Kajiyama H, Suzuki S, Sekiya R, Utsumi F, Shibata K, Taniguchi T, Kawaguchi K, Yokoi K, Kikkawa FT: The prognostic impact of pulmonary metastasectomy in recurrent gynecologic cancers: a retrospective single-institution study. Nagoya J Med Sci 2015, 77(3), 363-372.

Ba M, Long H, Wang Y, Tang Y, Wu Y, Zhang X, Cui S: Intrapleural hyperthermic perfusion using distilled water at 48 °C for malignant pleural effusion. J Cancer Res Clin Oncol 2013, 139(12), 2005-2012. https://doi.org/10.1007/s00432-013-1526-x

Barbetakis N, Asteriou C, Papadopoulou F, Samanidis G, Paliouras D, Kleontas A, Lyriti K, Katsikas I, Tsilikas C: Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J Cardiothorac Surg 2010, 5, 27. https://doi.org/10.1186/1749-8090-5-27

Barbetakis N, Vassiliadis M, Kaplanis K, Valeri R, Tsilikas C: Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer. BMC Palliat Care 2004, 3(1), 4. https://doi.org/10.1186/1472-684X-3-4

Cardillo G, Facciolo F, Carbone L, Regal M, Corzani F, Ricci A, Di Martino M, Martelli M: Long-term follow up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg 2002, 21, 302-306. https://doi.org/10.1016/S1010-7940(01)01130-7

Chi DS, Abu-Rustum NR, Sonoda Y, Chen SW, Flores RM, Downey R, Aghajanian C, Barakat RR: The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. Gynecol Oncol 2004, 94(2), 307-311. https://doi.org/10.1016/j.ygyno.2004.04.027

Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N: Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev 2016, 5, CD010529. https://doi.org/10.1002/14651858.CD010529.pub2

Davidson RS, Nwogu CE, Brentjens MJ, Anderson TM: The surgical management of pulmonary metastasis: current concepts. Surg Oncol 2001, 10, 35-42. https://doi.org/10.1016/S0960-7404(01)00013-5

Diaz JP, Abu-Rustum NR, Sonoda Y, Downey RJ, Park BJ, Flores RM, Chang K, Leitao MM Jr, Barakat RR, Chi DS: Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol Oncol 2010, 116(3), 483-488. https://doi.org/10.1016/j.ygyno.2009.09.047

Dvoretsky PM, Richards KA, Bonfiglio TA. The pathology and behavior of ovarian cancer. Path Ann 1989, 24, 1-24.

Fry WA, Khandekar JD. Parietal pleurectomy for malignant pleural effusion. Ann Surg Oncol 1995, 2(2), 160-164. https://doi.org/10.1007/BF02303632

Fuller AF Jr, Scannell JG, Wilkins EW Jr. Pulmonary resection for metastases from gynecologic cancers: Massachusetts General Hospital experience, 1943-1982. Gynecol Oncol 1985, 22, 174-180. https://doi.org/10.1016/0090-8258(85)90024-1

Gravelyn TR, Michelson MK, Gross BH. Tetracycline pleurodesis for malignant pleural effusions: a 10-year retrospective study. Cancer 1987, 59, 1973-1977. https://doi.org/10.1002/1097-0142(19870601)59:11<1973::AID-CNCR2820591124>3.0.CO;2-2

Guth U, Huang DJ, Bauer G, Stieger M, Wight E, Singer G: Metastatic patterns at autopsy in patients with ovarian carcinoma. Cancer 2007, 110(6), 1272-1280. https://doi.org/10.1002/cncr.22919

Hartman DL, Gaither JM, Kesler KA. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993, 105, 743-748.

Is1k AF, Sanl1 M, Y1lmaz M, Meteroglu F, Dikensoy O, Sevinc A, Camc1 C, Tuncozgur B, Elbeyli L: Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies. Respir Med 2013, 107(5), 762-767. https://doi.org/10.1016/j.rmed.2013.01.010

Juretzka MM, Abu-Rustum NR, Sonoda Y, Downey RJ, Flores RM, Park BJ, Hensley ML, Barakat RR, Chi DS: The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol Oncol 2007, 104, 670-674. https://doi.org/10.1016/j.ygyno.2006.10.010

Kerr VE, Cadman E. Pulmonary metastases in ovarian cancer. Analysis of 357 patients. Cancer 1985, 56, 1209-1213. https://doi.org/10.1002/1097-0142(19850901)56:5<1209::AID-CNCR2820560542>3.0.CO;2-Y

Kosuga T, Shiozaki A, Ichikawa D, Fujiwara H, Komatsu S, Iitaka D, Tsujiura M, Morimura R, Takeshita H, Nagata H, Okamoto K, Nakahari T, Marunaka Y, Otsuji E: Pleural lavage with distilled water during surgery for esophageal squamous cell carcinoma. Oncol Rep 2011, 26, 577-586.

Liu L, Zhang N, Min J, Su H, Wang H, Chen D, Sun L, Zhang H, Li W, Zhang H: Retrospective analysis on the safety of 5,759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy (HIPEC). Oncotarget 2016, 7(16), 21570-21578. https://doi.org/10.18632/oncotarget.7622

Lombardi G, Nicoletto MO, Gusella M, Fiduccia P, Dalla Palma M, Zuin A, Fiore D, Donach M, Zagonel V: Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. Cancer Chemother Pharmacol 2012, 69(3), 781-787. https://doi.org/10.1007/s00280-011-1765-y

McCormack PM, Bains MS, Begg CB, Burt ME, Downey RJ, Panicek DM, Rusch VW, Zakowski M, Ginsberg RJ: Role of videoassisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trial. Ann Thorac Surg 1996, 62, 213-217. https://doi.org/10.1016/0003-4975(96)00253-6

Montero CA, Gimferrer JM, Baldo X, Ramirez J: Mediastinal metastasis of ovarian carcinoma. Eur J Obstet Gynecol Rerprod Biol 2000, 91, 199-200. https://doi.org/10.1016/S0301-2115(99)00275-4

Moon Y, Kim KS, Park JK. Simple intrapleural hyperthermia at thoracoscopic exploration to treat malignant pleural effusion. J Cardiothorac Surg 2015, 28, 136. https://doi.org/10.1186/s13019-015-0340-8

Perri T, Ben-Baruch G, Kalfon S, Beiner ME, Helpman L, Hogen LB, Shapira-Frommer R, Korach J: Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: Is there a case for thoracic cytoreduction? Gynecol Oncol 2013, 131(1), 27-31. https://doi.org/10.1016/j.ygyno.2013.07.093

Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; BTS Pleural Disease Guideline Group: Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 2010, 65 (Suppl.2), 32-40. https://doi.org/10.1136/thx.2010.136994

Rose PG, Piver MS, Tsukada Y, Lau TS: Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 1989, 64(7), 1508-1513. https://doi.org/10.1002/1097-0142(19891001)64:7<1508::AID-CNCR2820640725>3.0.CO;2-V

Tangjitgamol S, Levenback CF, Beller U, Kavanagh JJ: Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. Int J Gynecol Cancer 2004, 14(3), 399-422. https://doi.org/10.1111/j.1048-891x.2004.14326.x

Thomas R, Francis R, Davies HE, Lee YC: Interventional therapies for malignant pleural effusions: the present and the future. Respirology 2014, 19, 809-822. https://doi.org/10.1111/resp.12328

Yim AP, Chan AT, Lee TW, Wan IY, Ho JK: Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996, 62, 1655-1658. https://doi.org/10.1016/S0003-4975(96)00808-9

Published
2017-08-31
How to Cite
Boyko, V., Kharchenko, K., Vereshchako, R., & Vakulenko, G. (2017). Thoracic surgery for ovarian cancer recurrence. Acta Medica Leopoliensia, 23(3), 31-38. https://doi.org/10.25040/aml2017.03.031